Island Pharmaceuticals

ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever.


  • All key data samples have been collected following dosing of all subjects in the Phase 2a (prophylactic) trial as part of Island’s ISLA-101 Phase 2a/b PROTECT clinical trial in dengue fever
  • Data currently being consolidated for review by the Safety Review Committee (SRC) in the coming weeks
  • On track to release SRC recommendation on advancing the trial to Phase 2b by end of this calendar year
In Island’s Phase 2a trial, subjects receive ISLA-101 before being infected with a weakened dengue virus developed by the US Army. The trial aims to assess whether ISLA-101 can prevent or reduce viremia and symptoms compared to a placebo, based on previous control data showing elevated viremia and symptoms in untreated subjects.

Following the announcement (ASX: 3 October 2024) that all subjects in the Phase 2a cohort of the trial had been dosed, Island confirms it has now collected the required samples to analyse how the viremia (viral load) levels in the blood of trial subjects have changed through the study. Other samples are being analysed for pharmacokinetic data as well as other blood analyses.

This data is currently being consolidated for review by the Safety Review Committee (SRC), who will meet in the coming weeks. The SRC will evaluate the safety of ISLA-101 in dengue infected individuals and consider if there is evidence of anti-dengue activity. They will then make a recommendation regarding advancing the trial to the Phase 2b cohort before the end of the calendar year.

Island’s CEO and Managing Director, Dr David Foster commented, “We are very pleased to be able to report that 46 days into the trial, we’ve collected the key data required for evaluation by the Safety Review Committee. From here, while we will continue to check in with patients up to 90 days post dosing, we look forward to providing all the data to the SRC for evaluation in the coming weeks. Importantly, this means we remain on track to report data before the end of the year from our Phase 2a component, and next steps for the Phase 2b cohort before the end of the year.”

Phase 2b will include 10 subjects randomised 8:2 (active: placebo) and will examine if ISLA-101 has activity as a treatment against dengue infection. This is the first time a potential countermeasure to combat the dengue virus, which afflicts more than 400 million individuals a year and for which there is no therapeutic option, is being investigated as both a preventative and therapeutic measure.

To subscribe to Island’s monthly newsletter, IslandWatch, and other forms of email communications, please visit this page of our website.


Click here for the full ASX Release

This article includes content from Island Pharmaceuticals, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

The Conversation (0)
Nutritional Growth Solutions Limited

Binding Commitments Received for A$1.0 Million under Convertible Note Placement

Nutritional Growth Solutions Limited (ASX:NGS) ("NGS" or "the Company"), is pleased to announce that it has received binding commitments for the issue of 1,000,000 convertible notes (Placement CNs), to be issued at $1.00 each (CN Placement).

Keep reading...Show less
AbbVie Reports First-Quarter 2025 Financial Results

AbbVie Reports First-Quarter 2025 Financial Results

  • Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46 , an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense
  • Delivers First-Quarter Net Revenues of $13.343 Billion , an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis
  • First   -Quarter Global Net Revenues from the Immunology Portfolio Were $6.264 Billion , an Increase of 16.6 Percent on a Reported Basis, or 18.1 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $3.425 Billion ; Global Rinvoq Net Revenues Were $1.718 Billion ; Global Humira Net Revenues Were $1.121 Billion
  • First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.282 Billion , an Increase of 16.1 Percent on a Reported Basis, or 17.0 Percent on an Operational Basis; Global Vraylar Net Revenues Were $765 Million ; Global Botox Therapeutic Net Revenues Were $866 Million ; Combined Global Ubrelvy and Qulipta Net Revenues Were $433 Million
  • First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.633 Billion , an Increase of 5.8 Percent on a Reported Basis, or 7.5 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $738 Million ; Global Venclexta Net Revenues Were $665 Million ; Global Elahere Net Revenues Were $179 Million
  • First   -Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.102 Billion , a Decrease of 11.7 Percent on a Reported Basis, or 10.2 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $556 Million ; Global Juvederm Net Revenues Were $231 Million
  • Raises 2025 Adjusted Diluted EPS Guidance Range from $11.99 - $12.19 to $12.09 - $12.29 , which Includes an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the First Quarter 2025

- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2025 .

"AbbVie's first-quarter results were well ahead of our expectations and reflect an excellent start to the year," said Robert A. Michael , chief executive officer, AbbVie. "The fundamentals of our business are strong and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE  for the Treatment of Glabellar Lines

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE for the Treatment of Glabellar Lines

TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind available to patients. –Submission is supported by data from over 2,100 patients treated with TrenibotE throughout the clinical program.

NORTH CHICAGO, Ill. , April 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Adicet Bio Appoints Michael Grissinger to the Board of Directors

--Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions--

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Neuroscientific Biopharmaceuticals

Neuroscientific to Acquire Leading Stem Cell Technology

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) to acquire StemSmartTM patented Stem Cell technology (StemSmart), for the manufacture of life-changing cellular medicine, Mesenchymal Stromal Cells (MSC), from Isopogen WA Ltd (Isopogen WA).

Keep reading...Show less

Latest Press Releases

Related News

×